Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Plavix · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Clopidogrel Bisulfate Tablets 75 mg |
| 2 | ACTIVE_COMPARATOR | Plavix® Tablets 75 mg |
| Name | Type | Description |
|---|---|---|
| Clopidogrel Bisulfate Tablets 75 mg | DRUG | 75mg, single dose fasting |
| Plavix® Tablets 75 mg | DRUG | 75mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 14 days prior to the start of the study and on the evening prior to each dose administ...
Plavix is a small molecule drug being developed by Viatris Inc. (VTRS). In the clinical trials listed, it is studied in healthy volunteers for bioequivalence purposes, comparing clopidogrel bisulfate tablets to Plavix tablets. The indication is listed as Healthy, meaning the trials enroll healthy participants rather than patients with a specific disease.
Plavix is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The clinical trials are conducted in the United States and involve healthy volunteers.
Plavix is in Phase 1 clinical development. The two trials listed are both Phase 1 studies, and both have been completed. There are no active trials currently listed for Plavix.
Plavix has two completed Phase 1 trials: NCT00648947, a fasting study of clopidogrel bisulfate tablets 75 mg compared to Plavix tablets 75 mg, and NCT00650169, a food study of the same comparison. Both enrolled healthy volunteers in the United States, with a total enrollment of 93 participants.
Plavix is the brand name for clopidogrel bisulfate. The clinical trials compare generic clopidogrel bisulfate tablets to the Plavix brand tablets to assess bioequivalence. The trials are designed to show that the generic version works the same as the branded Plavix.